SEC Form 4 · accession 0001178913-18-000726

Foamix Pharmaceuticals Ltd. · FOMX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP R&D

Period of report

Feb 27, 2018

Accepted (ET)

Feb 28, 2018 · 4:12 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001606645

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Ordinary Shares^F2,F1,F3	Feb 27, 2018	A	10,000	$0.00	A	37,000	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Options^F4,F5	$6.35	Feb 27, 2018	A	30,000	A	—	Feb 27, 2028	Ordinary Shares	30,000	30,000	D

F1This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
F2The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.
F3The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 27,000 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security and (ii) the 10,000 ordinary shares sub-ject to unvested restricted share units granted on February 27, 2018 and first reported on this Form 4.
F4Each option represents a contingent right to purchase one ordinary share of the issuer.
F5The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.